Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/13836
Title: Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection.
Authors: Santos, Thaís Teodoro de Oliveira
Machado, Amanda Sanchez
Ramos, Fernanda Fonseca
Silva, João Augusto Oliveira da
Lage, Daniela Pagliara
Tavares, Grasiele de Sousa Vieira
Mendonça, Débora Vasconcelos Costa
Cardoso, Mariana Santos
Siqueira, Williane Fernanda
Martins, Vívian Tamietti
Ribeiro, Fernanda Ludolf
Reis, Thiago Alves Rosa dos
Carvalho, Lívia Mendes
Freitas, Camila Simões de
Bandeira, Raquel Soares
Silva, Alessandra M.
Oliveira, Jamil Silvano de
Moreira, Ricardo Luiz Fontes
Fujiwara, Ricardo Toshio
Roatt, Bruno Mendes
Chávez Fumagalli, Miguel Angel
Humbert, Maria Victoria
Teixeira, Antônio Lúcio
Coelho, Eduardo Antônio Ferraz
Keywords: Visceral leishmaniasis
Vaccine
Recombinant protein
DNA vaccine
Issue Date: 2021
Citation: SANTOS, T. T. de O. et al. Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection. Microbial Pathogenesis, v. 151, artigo 104745, fev. 2021. Disponível em: <https://www.sciencedirect.com/science/article/abs/pii/S0882401021000176?via%3Dihub>. Acesso em: 10 jun. 2021.
Abstract: Treatment for visceral leishmaniasis (VL) is hampered mainly by the toxicity and/or high cost of antileishmanial drugs. What is more, variability on sensitivity and/or specificity of diagnostic tests hinders effective disease management. In this context, prophylactic vaccination should be considered as a strategy to prevent disease. In the present study, immunogenicity of the Leishmania eukaryotic Elongation Factor-1 beta (EF1b) protein, classified as a Leishmania virulence factor, was evaluated in vitro and in vivo and tested, for the first time, as a vaccine candidate against Leishmania infantum infection. The antigen was administered as DNA vaccine or as recombinant protein (rEF1b) delivered in saponin. BALB/c mice immunization with a DNA plasmid and recombinant protein plus saponin induced development of specific Th1-type immunity, characterized by high levels of IFN-γ, IL-12, GM-CSF, both T cell subtypes and antileishmanial IgG2a isotype antibodies, before and after infection. This immunological response to the vaccines was corroborated further by parasitological analysis of the vaccinated and then challenged mice, which showed significant reductions in the parasite load in their liver, spleen, bone marrow and draining lymph nodes, when compared to the controls. Vaccination using rEF1b/saponin induced a more robust Th1 response and parasitological protection when compared to the DNA vaccine. Furthermore, in vitro analysis of lymphoproliferation, IFN-γ and IL-10 levels in human PBMC cultures showed as well development of a specific Th1-type response. In conclusion, data suggest that EF1b could be a promising vaccine candidate to protect against L. infantum infection.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/13836
metadata.dc.identifier.uri2: https://www.sciencedirect.com/science/article/abs/pii/S0882401021000176?via%3Dihub
metadata.dc.identifier.doi: https://doi.org/10.1016/j.micpath.2021.104745
ISSN: 0882-4010
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_LeishmaniaEukaryoticEnlogation.pdf
  Restricted Access
3,85 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.